Navigating the Nomenclature of a Purported “Dietary Supplement”: A Cautionary Tale for Consumers and Practitioners Regarding Tianeptine or “Gas Station Heroin” — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Navigating the Nomenclature of a Purported “Dietary Supplement”: A Cautionary Tale for Consumers and Practitioners Regarding Tianeptine or “Gas Station Heroin”
Center for Nutraceutical and Dietary Supplement Research, College of Health Sciences, University of Memphis, Memphis, TN, USA
1 Center for Nutraceutical and Dietary Supplement Research, College of Health Sciences, University of Memphis, Memphis, TN, USA
Dietary supplement sales have surpassed $30 billion per year with their use becoming and remaining extremely popular amongst the general public. There are numerous bioactive components, both nutritive and non-nutritive, in dietary supplements with considerable efficacy in promoting health. However, there are many ways disallowed ingredients may enter the supplement pipeline with potentially toxic effects. Dietary supplements can be regulated (either pre- or post-market) as a drug, dietary supplement, a nutraceutical, new dietary ingredient (NDI), generally recognized as safe (GRAS) food ingredient, a food additive, or a food. A pharmaceutical drug (medication) is used to treat, cure, prevent, or diagnose a disease and is regulated by the FDA pre-market only and allowed by medical prescription, whereas the other labeling designations are largely regulated post-market. One such molecule with a labeling problem is tianeptine, which has global use as an efficacious, prescribed drug, while at the same time being considered a non-drug and potentially dangerous adulterant often referred to as gas station heroin. In this paper, we critically evaluate the use and labeling of this compound and attempt to clarify the conundrum surrounding its legal or illegal use. Tianeptine is effective and efficacious as an antidepressant in those responding poorly to selective serotonin reuptake inhibitors (SSRIs) and exhibits many medicinal characteristics of tricyclic antidepressants with fewer opioid-like side effects. As a result, sixty-six countries permit use of tianeptine as a prescription drug. At higher doses, tianeptine has recently been shown to exhibit significant potential for abuse and dependency along with toxicity. As such, the US does not recognize tianeptine as an FDA-approved drug or as a dietary supplement, nutraceutical, new dietary ingredient (NDI), GRAS ingredient, or a food. Instead, tianeptine is a synthetic adulterant of a dietary supplement and considered technically an unapproved food additive. In conclusion, tianeptine, although viewed as a safe dietary supplement by many, is illegal in the US despite benefits to many but toxicity to others that make it vital that consumers and healthcare providers learn to critically evaluate and navigate the often confusing nomenclature of a purported dietary supplement to convey to the public whether it is efficacious, safe, and legal.
Pawar, R.S. and Grundel, E. (2017) Overview of Regulation of Dietary Supplements in the USA and Issues of Adulteration with Phenethylamines (PEAs). Drug Testing and Analysis, 9, 500-517. https://doi.org/10.1002/dta.1980
Tucker, J., Fischer, T., Upjohn, L., Mazzera, D. and Kumar, M. (2018) Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated with US Food and Drug Administration Warnings. JAMA Network Open, 1, e183337. https://doi.org/10.1001/jamanetworkopen.2018.3337
Bailey, R.L., Gahche, J.J., Lentino, C.V., et al. (2011) Dietary Supplement Use in the United States, 2003-2006. The Journal of Nutrition, 141, 261-266. https://doi.org/10.3945/jn.110.133025
Burdock, G.A. (2006) The Importance of GRAS to the Functional Food and Nutraceutical Industries. Toxicology, 221, 17-27. https://doi.org/10.1016/j.tox.2006.01.012
Kasper, S. and Olie, J.P. (2002) A Meta-Analysis of Randomized Controlled Trials of Tinaeptine versus SSRI in the Short-Term Treatment of Depression. European Psychiatry, 17, 331-340. https://doi.org/10.1016/S0924-9338(02)00651-X
Brink, C.B., Harvey, B.H. and Brand, L. (2006) Tianeptine: A Novel Atypical Antidepressant That May Provide New Insights into the Biomolecular Basis of Depression. Recent Patents on CNS Drug Discovery, 1, 29-41. https://doi.org/10.2174/157488906775245327
Wagstaff, A.J., Ormrod, D. and Spencer, D.M. (2001) Tianeptine: A Review of Its Use in Depressive Disorders. CNS Drugs, 15, 231-259. https://doi.org/10.2165/00023210-200115030-00006
McEwen, B.S. and Olie, J.P. (2005) Neurobiology of Mood, Anxiety, and Emotions as Revealed by Studies of a Unique Antidepressant: Tianeptine. Molecular Psychiatry, 10, 525-537. https://doi.org/10.1038/sj.mp.4001648
Wilde, M.I. (1996) Tianeptine: A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Depression and Coexisting Anxiety and Depression. Drugs, 49, 411-439. https://doi.org/10.2165/00003495-199549030-00007
Zoladz, P.R., Park, C.R., Munoz, C., Fleshner, M. and Diamond, D.M. (2008) Tianeptine: An Antidepressant with Memory-Protective Properties. Current Neuropharmacology, 4, 311-321. https://doi.org/10.2174/157015908787386096
Allain, F., Ehrlich, A.T., McNicholas, M., Gross, F., Ma, W., Kieffer, B.L. and Daroq, E. (2023) Chronic Tianeptine Induces Tolerance in Analgesia and Hyperlocomotion via Mu-Opioid Receptor Activation in Mice. Frontiers in Psychiatry, 14, Article 1186397. https://doi.org/10.3389/fpsyt.2023.1186397
Pharmaceutical
Nutraceutical
GRAS
NDI
Gassaway, M.M., Rives, M.L., Kruegel, A.C., Javitch, J.A. and Sames, D. (2014) The Atypical Antidepressant and Neurorestorative Agent Tianeptine is a μ-Opioid Receptor Agonist. Translational Psychiatry, 4, e411. https://doi.org/10.1038/tp.2014.30
Herman, T.F., Cascella, M. and Muzio, M.R. (2023) Mu Receptors. StatPearls, Treasure Island. https://www.ncbi.nlm.nih.gov/books/NBK551554/
Reagan, L.P., Hemndry, R.M., Rezbikov, L.R., Piroli, G.G., Wood, G.E., McEwen, B.S. and Grillo, C.A. (2007) Taineptine Increases Brain-Derived Neurotrophic Factor Expression in the Rat Amygdala. European Journal of Pharmacology, 565, 68-75. https://doi.org/10.1016/j.ejphar.2007.02.023
Kole, M.H.P., Swan, L. and Fuchs, E. (2022) The Antidepressant Tianeptine Persistently Modulates Glutamate Receptor Currents of the Hippocampal CA3 Commissural Associational Synapse in Chronically Stressed Rats. European Journal of Neuroscience, 6, 807-816. https://doi.org/10.1046/j.1460-9568.2002.02136.x
Smith, E., Rogers, J., Strickland, J.C. and Epstein, D.H. (2021) When an Obscurity Becomes a Trend: Social-Media Descriptions of Tianeptine Use and Associated Atypical Drug Use. The American Journal of Drug and Alcohol Abuse, 47, 455-466. https://doi.org/10.1080/00952990.2021.1904408
Ari, M., Oktar, S. and Duru, M. (2010) Amitriptyline and Tianeptine Poisoning Treated by Naloxone. Human & Experimental Toxicology, 29, 793-795. https://doi.org/10.1177/0960327110372403
Samuels, B.A., Nautiyal, K.M., Kruegel, A.C., et al. (2017) The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor. Neuropsychopharmacology, 42, 2052-2063. https://doi.org/10.1038/npp.2017.60
Lauhan, R., Hsu, A., Alam, A. and Beizai, K. (2018) Tianeptine Abuse and Dependence: Case Report and Literature Review. Psychosomatics, 59, 547-553. https://doi.org/10.1016/j.psym.2018.07.006
Evans, E.A. and Ma, S. (2014) Abuse and Misuse of Antidepressants. Substance Abuse and Rehabilitation, 5, 107-120. https://doi.org/10.2147/SAR.S37917
Edinoff, A.N., Sall, S., Beckman, S.P., Koepnick, A.D., Gold, L.C., Jackson, E.D., Wenger, D.M., Cornett, E.M., Murnane, K.S., Kaye, A.M. and Kaye, A.D. (2023) Tianeptine, an Antidepressant with Opioid Agonist Effects: Pharmacology and Abuse Potential, a Narrative Review. Pain and Therapy, 12, 1121-1134. https://doi.org/10.1007/s40122-023-00539-5
Baird, T.R., Akbarali, H.I., Dewey, W.L., Elder, H., Kang, M., Marsh, S.A., Peace, M.R., Poklis, J.L., Santos, E.J. and Negus, S.S. (2022) Opioid-Like Adverse Effects of Tianeptine in Male Rats and Mice. Psychopharmacology, 239, 2187-2199. https://doi.org/10.1007/s00213-022-06093-w
El Zahran, T., Schier, J., Glidden, E., Kieszak, S., Law, R., Bottei, E., Aaron, C., King, A. and Chang, A. (2018) Characteristics of Tianeptine Exposures Reported to the National Poison Data System—United States, 2000-2017. Morbidity and Mortality Weekly Report, 67, 815-818. https://doi.org/10.15585/mmwr.mm6730a2
Marraffa, J.M., Stork, C.M., Hoffman, R.S. and Su, M.K. (2018) Poison Control Center Experience with Tianeptine: An Unregulated Pharmaceutical Product with Potential for Abuse. Clinical Toxicology, 56, 1155-1158. https://doi.org/10.1080/15563650.2018.1476694
Guelfi, J.D., Duloire, C., Le Moine, P. and Tafani, A. (2002) Clinical Safety and Efficacy of Tianeptine in 1858 Depressed Patients Treated in General Practice. Neuropsychobiology, 25, 140-148. https://doi.org/10.1159/000118824
McEwen, B.S., Magarinos, A.M. and Reagan, L.P. (2002) Structural Plasticity and Tianeptine: Cellular and Molecular Targets. European Psychiatry, 17, 318-330. https://doi.org/10.1016/S0924-9338(02)00650-8
McEwen, B.S. and Chattarji, S. (2004) Molecular Mechanisms of Neuroplasticity and Pharmacological Implications: The Example of Tianeptine. European Neuropsychopharmacology, 14, S497-S502. https://doi.org/10.1016/j.euroneuro.2004.09.008
McEwen, B.S., Chattarji, S., Diamond, D.M., Jay, T.M., Reagan, L.P., Svenningsson, P. and Fuchs, E. (2010) The Neurobiological Properties of Tianeptine (Stablon): From Monoamine Hypothesis to Glutamatergic Modulation. Molecular Psychiatry, 15, 237-249. https://doi.org/10.1038/mp.2009.80
Kasper, S. and McEwen, B.S. (2008) Neurobiological and Clinical Effects of the Antidepressant Tianeptine. CNS Drugs, 22, 15-26. https://doi.org/10.2165/00023210-200822010-00002
Andras, S. (2008) “Atypical” Antidepressive Mechanisms: Glutamatergic Modulation and Neuroplasticity in Case of Tianeptin. Neuropsychopharmacologia Hungarica, 10, 305-313.
García-Alberca, J.M., Gris, E., de la Guía, P. and Mendoza, S. (2022) Effects of Tianeptine Treatment on Depression and Cognitive Function in Patients with Alzheimer’s Disease: A 12-Month Retrospective Observational Study. Journal of Alzheimer’s Disease, 88, 707-720. https://doi.org/10.3233/JAD-215630
Alamo, C., Garcia-Garcia, P., Lopez-Munoz, F. and Zaragoza, C.P. (2019) Tianeptine, an Atypical Pharmacological Approach to Depression. Revista de Psiquiatría y Salud Mental, 12, 170-186. https://doi.org/10.1016/j.rpsm.2018.09.002
Kisa, C., Bulbul, D.O., Aydemir, C. and Goka, E. (2007) Is It Possible to Be Dependent to Tianeptine, an Antidepressant? A Case Report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31, 776-778. https://doi.org/10.1016/j.pnpbp.2007.01.002
Drug Enforcement Administration and Department of Justice (2020) Drugs of Abuse. A DEA Resource Guide.
Bailey, R.L. (2020) Current Regulatory Guidelines and Resources to Support Research of Dietary Supplements in the United States. Critical Reviews in Food Science and Nutrition, 60, 298-309. https://doi.org/10.1080/10408398.2018.1524364
Dickinson, A. (2011) History and Overview of DSHEA. Fitoterapia, 82, 5-10. https://doi.org/10.1016/j.fitote.2010.09.001
Mister, S. and Hathcock, J. (2012) Under the Law, FDA Must Grant Different Standards for New Dietary Ingredients and Food Additives. Regulatory Toxicology and Pharmacology, 62, 456-458. https://doi.org/10.1016/j.yrtph.2012.01.006
Burdock, G.A. (2000) Dietary Supplements and Lessons to Be Learned from GRAS. Regulatory Toxicology and Pharmacology, 31, 68-76. https://doi.org/10.1006/rtph.1999.1369
Burdock, G.A. and Carabin, I.G. (2004) Generally Recognized as Safe (GRAS): History and Description. Toxicology Letters, 150, 3-18. https://doi.org/10.1016/j.toxlet.2003.07.004
Dellaleau, B., Dulcire, C., Le Moine, P. and Kamoun, A. (1988) Analysis of the Side Effects of Tianeptine. Clinical Neuropharmacology, 11, S83-S89.
Wagner, M.L., Pergolizzi, J., LeQuang, J.K., Breve, F. and Varrassi, G. (2023) From Antidepressant Tianeptine to Street Drug ZaZa: A Narrative Review. Cureus, 15, e40688. https://doi.org/10.7759/cureus.40688
Rushton, W., Whitworth, B., Bron, J., Kurz, M. and Rivera, J. (2021) Characteristics of Tianeptine Effects Reported to a Poison Control Center: A Growing Threat to Public Health. Clinical Toxicology, 59, 152-157. https://doi.org/10.1080/15563650.2020.1781151
Hargett, J.L., Lowry, P.F. and Lee, K.N. (2023) Nursing Implications for Tianeptine Use and Misuse. Journal of Addictions Nursing, 34, 158-161. https://doi.org/10.1097/JAN.0000000000000535
Trowbridge, P. and Walley, A.Y. (2019) Use of Buprenorphine-Naloxone in the Treatment of Tianeptine Use Disorder. Journal of Addictions Nursing, 13, 331-333. https://doi.org/10.1097/ADM.0000000000000490